31 October 2019

Radboud university medical center and Quirem Medical signed an agreement for joint research. The agreement includes several existing and future projects based on small radioactive spheres (holmium-166 microspheres). Enhanced cooperation should improve the treatment of cancer patients and stimulate research into new applications.
  
“Radboudumc strives for continuous improvement of patient care,” says Professor Jurgen Fütterer, intervention radiologist at Radboudumc. “Because we are involved in the development of new treatment techniques, we can tailor these techniques as closely as possible to the needs of the patient. The expansion of our cooperation with Quirem Medical fits in perfectly with that aim.”
 
Person-oriented treatment
The research into holmium microspheres in Radboudumc takes place in the Radiology and Nuclear Medicine department. The 'nuclear local interventions' are carried out in close cooperation with Jurgen Fütterer and other researchers at the Department of Nuclear Medicine. Fütterer: “Our special MITeC operating theatres enable us to use MRI imaging to show the location of the radioactive holmium spheres during the treatment. This allows treatment that is precisely tailored to the individual.”
 
Image-guided treatment
Quirem Medical, located in Deventer, is the result of previous innovations by the Nijsen research group. “We have also developed radioactive polylactic acid microspheres for the treatment of liver tumors, called radio embolization,” says Fütterer. "We are now focusing on further refining this image-guided treatment to get an even higher dose into patients' liver tumors. We are also working on similar treatments for pancreatic and brain tumors where we will also apply radiation directly to the tissues themselves. These are developing techniques that Quirem Medical, together with Radboudumc, will try to introduce to the clinic in the coming years."
 
Working together on innovative applications
Quirem Medical develops and produces holmium-166 microspheres for the treatment of tumors. CEO Jan Sigger: “The radioactive holmium microspheres ensure that the tumors are irradiated locally. Moreover, thanks to the holmium, we can see exactly where the microspheres are and whether there are enough microspheres surrounding the tumor. Our technology is currently being used to treat liver tumors that are no longer operable. Radboudumc offers state-of-the-art research, pre-clinical and clinical facilities that offer excellent opportunities to support and accelerate the development of new applications. The high-quality hot lab facilities in the Radboud Translational Medicine center can also help in the further development of our pipeline of innovative, new applications.”


About Quirem Medical
Quirem Medical is a growing medical device company that is developing the next generation of microspheres for targeted interventional treatment of liver tumors. Quirem Medical is based in Deventer, the Netherlands.

 

Related news items


The Postdoctoral Networking Tour in artificial intelligence

2 July 2020

You are a postdoctoral researcher in the field of artificial intelligence? The Postdoc-NeT-AI offers you the opportunity to participate in one week of on-site visits to leading German universities, research institutes and companies. Apply now to this year's tour until 16 August 2020.

read more

Register for Phd courses via gROW What does this mean for you?

2 July 2020

From now on you can arrange everything related to the general RU PhD courses via gROW. Because of this there will be some changes in the registration! What does this mean for you?

read more

Experts on metabolic diseases still an unknown major problem...

1 July 2020

Six Dutch UMCs and a patient association contribute to treating and solving this major, often unknown, problem. Timely detection of metabolic diseases is vital. Therefore, Radboudumc is also part of the consortium “United for Metabolic Diseases”.

read more

Radboud Pluim for Lionne Ekers ambassador for the RIMLS institute

30 June 2020

Lionne Ekers received the Radboudpluim for her special merits for the Radboudumc. She is a born ambassador for our Institute.

read more

Stefan Listl member Lancet Commission on Oral Health

29 June 2020

In recognition of the global public health importance, woeful neglect of oral diseases, and the need for a broader understanding and commitment to global oral health within medicine and global health agendas, The Lancet recently established a Commission on Oral Health.

read more

Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

29 June 2020

In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.

read more